Casirivimab and imdevimab

Therapeutic indications

Casirivimab and imdevimab is indicated for:

COVID-19

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Casirivimab/imdevimab combination is indicated for:

  • Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
  • Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

COVID-19

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Casirivimab/imdevimab combination is indicated for prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: RONAPREVE Solution for injection/infusion
Summary of Product Characteristics (SPC) 2021: RONAPREVE Solution for injection/infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈